AIMC Topic: Rituximab

Clear Filters Showing 1 to 10 of 14 articles

Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis.

Nature communications
Approximately 40% of patients with rheumatoid arthritis do not respond to individual biologic therapies, while biomarkers predictive of treatment response are lacking. Here we analyse RNA-sequencing (RNA-Seq) of pre-treatment synovial tissue from the...

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.

BMJ open
INTRODUCTION: Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy. However, Kidney Dise...

Deep learning-based organ-wise dosimetry of Cu-DOTA-rituximab through only one scanning.

Scientific reports
This study aimed to generate a delayed Cu-dotatate (DOTA)-rituximab positron emission tomography (PET) image from its early-scanned image by deep learning to mitigate the inconvenience and cost of estimating absorbed radiopharmaceutical doses. We acq...

Could machine learning revolutionize how we treat immune thrombocytopenia?

British journal of haematology
The absence of reliable biomarkers in immune thrombocytopenia (ITP) complicates treatment choice, necessitating a trial-and-error approach. Machine learning (ML) holds promise for transforming ITP treatment by analysing complex data to identify predi...

Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction.

Frontiers in immunology
Recombinant DNA technology has, in the last decades, contributed to a vast expansion of the use of protein drugs as pharmaceutical agents. However, such biological drugs can lead to the formation of anti-drug antibodies (ADAs) that may result in adve...

Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy.

Cancer medicine
Vitamin D deficiency has been reported to be a negative prognostic factor in elderly patients with aggressive B-cell lymphomas. In vitro data suggest that vitamin D supplementation may enhance rituximab-mediated cytotoxicity. We prospectively assesse...

Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms.

Clinical and experimental medicine
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses significant therapeutic challenges due to heterogeneous patient outcomes. This study aimed to evaluate the efficacy of the ibrutinib plus R-ICE regimen and to leverage explainable mac...